IRVINE, Calif.–(BUSINESS WIRE)–Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today commented on Valeant Pharmaceuticals International, Inc.’s (“Valeant”) release of its second quarter 2014 earnings results. Following Valeant’s earnings conference call on July 31, 2014, Allergan’s financial advisors and forensic accountants analyzed Valeant’s reported financial and operating results, identifying numerous inconsistencies and omissions. Further, Valeant’s 46-page July 31 second quarte
I currently bootstrap @Hackyourstyle, @Syntezia and @Agilenetup. I also help @panglosslabs1 @lepole.education and @yoursoftweb. My passion is to help scale ups and corporates stay creative, innovative and up to date with new business models. I specialise in rapid prototyping, competitive intelligence, open innovation and strategic agility. We follow the latest developments in social media, cloud computing, in 3D (printing, scan, manufacturing) in mobile apps and games, as well as in big data. semantics, text analytics and HR analytics technologies. We have developed a special interest the Open Education trends and what happens with the MOOCs. As a Corporate Responsability Ambassador, I regurlarly talk about ethics as a conference speaker, or as a moderator, and I have recently been awarded as "Equal Salary Ambassador". I am active on Twitter, Facebook, Github, Google+, Pinterest, Quora, Instagram, Persiscope and LinkedIN, you can find all the links in the Contact section. Very keen to interact with you.